PET FDG Assessment of Change in Atherosclerotic Plaques After Chemotherapy

Tel Aviv Sourasky Medical Center

Status: Unknown

Conditions: Atherosclerosis

Study type: Observational

Funder types: Other

Identifiers

NCT00742352

TASMC-08-EES-253-CTIL

Details and patient eligibility

About

The purpose of this study is to determine whether chemotherapy induces regression in atherosclerotic plaques in oncologic patients already undergoing PET FDG as part of their routine assessment.We will use PET FDG to assess whether the inflammation in atherosclerotic plaques is affected by chemotherapy and anti angiogenic therapy.

Enrollment: 40 estimated patients

Sex: All

Ages: 65+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Women over the age of 65 diagnosed with metastatic breast cancer
• Men over the age of 65 diagnosed with lung cancer

Exclusion criteria

• Patients under the age of 65
• Patients diagnosed with chronic inflammatory disease or chronic infection
• Patients taking steroids and NSAIDS on a regular basis

Trial design

40 participants in 2 patient groups

Breast cancer patients

Lung cancer patients